Abstract: The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (1): and pharmaceutically acceptable salts thereof, wherein Cy, R1 and R2 are as defined herein. The invention further relates to the use of the compounds of formula (1) in combination with sodium-glucose cotransporter-2 (SGLT2) inhibitors.

Abstract: The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.

Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.

Abstract: A cartridge for a dispensing device, such as a nebulizer, for dispensing a medicament composed of or produced from a plurality of components and a system including a dispensing device, such as a nebulizer, and such a cartridge. The cartridge includes at least two fluidically separated chambers which each contain at least one component of the medicament, an actuating mechanism for fluidically connecting the chambers and mixing the components for the dispensing of the medicament. A method for preparing a medicament composed of a plurality of components in a cartridge for the dispensing of said medicament by way of a dispensing device, such as a nebulizer, where a plurality of fluidically separated chambers of the cartridge are fluidically connected, and a component of the medicament is at least partially transferred from one of the chambers to another of the chambers with another component of the medicament in order to mix the components.

Abstract: Methods of treating or preventing alcoholic liver disease are disclosed, the methods comprising administering to a subject a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling.

Abstract: The present invention encompasses compounds of the formula I which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Abstract: The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitor of formula III or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to methods for treating patients with compensated cirrhosis, comprising administering to a patient in need thereof a therapeutically effective amount of a soluble guanylate cyclase (sGC) activator, or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides a method of suppressing gene expression, comprising providing a mammalian cell with a suppression target RNA molecule comprising a heterologous RNAi target site operatively linked to a RNA sequence from a gene of interest, or with a DNA encoding said suppression target RNA molecule; providing to the cell an inhibitory RNA that has a complementary nucleotide sequence to the heterologous RNAi target site; wherein binding of the inhibitory RNA to the heterologous RNAi target site suppresses gene expression of the operatively linked RNA sequence from the gene of interest; and wherein said heterologous RNAi target site has a size of at least 18 nucleotides in length. The invention further provides nucleic acids and cells suitable for such a method.

Abstract: The invention relates to new pyridinyl sulfonamide derivatives of the formula wherein R1, A and n are as defined herein, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Abstract: A viral inactivation device including at least one experimental continuous viral inactivation reactor having at least an inlet, an outlet, and a tubular flow path and a computer system that, based on the experimental continuous viral inactivation reactor can design, select, make, and/or manufacture a scaled actual reactor. The tubular flow path includes a set of alternating turns that form a serpentine or an interwoven pattern between the inlet and the outlet.

Abstract: Methods of protein production in a linked culture and production bioreactor system are provided. Such methods include a culture bioreactor (N?1 bioreactor) linked to production bioreactor (N bioreactor). More specifically, the methods include (a) culturing cells with a gene that encodes the protein of interest in a continuous perfusion culture bioreactor (N?1 bioreactor); inoculating a continuously stirred tank reactor (CSTR) production bioreactor (N bioreactor) with cells obtained from step (a); and culturing the cells in the CSTR production bioreactor under conditions that allow production of the protein of interest.

Abstract: The present invention encompasses compounds of formula (1) wherein the groups R1, A, G, LK and t have the meanings given in the claims and specification, their use as degraders of SMARCA2 and/or SMARCA4, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

Abstract: The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

Abstract: The present disclosure provides certain 3H,4H-thieno[2,3-d]pyrimidin-4-one derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.

Abstract: The invention relates to new pyridinyl sulfonamide derivatives of the formula wherein R1, A and n are as defined herein, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Abstract: Methods of protein production in continuous perfusion mammalian cell culture bioreactors are provided. Methods for continuous perfusion culture by allowing cells to self-regulate the rate of addition of perfusion medium to the bioreactor via a pH change are presented. Compositions comprising the perfusion medium as well as the process advantages of using hi-end pH control of perfusion or HIPCOP are also presented.

Abstract: The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

Abstract: The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CD80 extracellular domain Fc-fusion protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.